Marta Navratil, MD, PhD, Department of Pulmonology, Allergology, Rheumatology and Clinical Immunology, Children's Hospital Zagreb, Klaićeva 16, 10000 Zagreb, Croatia;
Acta Dermatovenerol Croat. 2021 Nov;29(4):238-240.
We present a case of a 10-year-old boy with a longstanding history of seborrheic dermatitis (SD) referred to the Allergy and Immunology Department for recurrent Kaposi varicelliform eruption (KVE) secondary to herpes simplex 1 (HSV-1) infection and possible primary immunodeficiency. The patient was the second child of non-consanguineous parents, with an older, healthy brother. Family history was negative for primary immunodeficiency and skin disorders. The patient's skin problems began in infancy when he was diagnosed and treated by a dermatologist for SD. From preschool age, he was under the care of a pediatric neurologist and a defectologist for a sensory processing disorder. For the last two years, the patient had been receiving chlorpromazine therapy for aggressive behavior. The first episode of KVE was diagnosed at the age of six, following potent topical corticosteroid therapy for SD and sun exposure, another known risk factor for HSV infection. After the third KVE episode, prophylaxis with oral acyclovir was initiated. The skin changes were treated with topical steroids and oral antibiotics during disease flares, with poor clinical response. On presentation, the patient was in good general health, adipose, and of unremarkable somatic status, except for numerous symmetrical yellowish-brown keratotic papules and plaques on the forehead, cheeks, and the lateral side of the neck (Figure 1). The nail plate had multiple red and white longitudinal streaks and V-shaped notches on the distal free end of the nail plate (Figure 2). The allergy tests revealed increased total immunoglobulin E (IgE) and sensitization to ragweed. Immunological workup showed normal immunoglobulins and good specific immunity (good vaccine response and normal humoral response to HSV-1) but a decreased number of T- cells (CD3+ 1020/µL (1320-3300), CD3+CD8+ 281/µL (390-1100) with normal T-cell response after antigen stimulation. The diagnosis of Darier disease (DD) was confirmed based on medical history, clinical findings and histological finding of focal suprabasal acantholysis and dyskeratosis (Figure 3). Low-dose oral retinoid therapy was initiated with modest clinical response after 6 months of therapy. In the light of recent publication (1), we initiated intravenous immunoglobulin (IVIG) substitution (400 mg/kg every month) with excellent clinical response. After 4 months, the patient's skin improved in terms of reduced inflammation, scab healing, and reduced itching. Acyclovir prophylaxis was continued. The patient had no new episodes of KVE during follow-up. Kaposi's varicelliform eruption (KVE) or eczema herpeticum occurs in a chronic inflammatory skin disease such as atopic dermatitis (AD), SD, Hailey-Hailey disease, allergic contact dermatitis, psoriasis, and DD (2). It is considered a dermatologic emergency due to its high mortality rate if misdiagnosed or left untreated (3). DD is a rare autosomal dominant genodermatosis of variable expressivity caused by mutations in the ATP2A2 gene, which encodes a sarco/endoplasmic reticulum calcium ATPase (SERCA2) highly expressed in keratinocytes (4). The onset of the disease usually occurs between the ages of 6 and 20 years. There are several clinical variants of DD: hypertrophic, verrucous, vesicular-bullous (dyshidrotic), erosive, and predominantly intertriginous forms (4). The fact that skin lesions occurred in infancy and a negative family history for skin diseases could be the reason our patient was initially misdiagnosed with seborrheic dermatitis. Due to the variable expressivity of the disease, it is impossible to exclude the diagnosis in other family members, and genetic testing of the patient and family members is therefore planned. A co-occurrence of neuropsychiatric abnormalities such as epilepsy, mental impairment, and mood disorders have been reported in patients with Darier disease, and these disorders were also present in our patient (5), indicating a correct diagnosis. Patients with DD have a high propensity for severe viral, bacterial, and fungal skin infection, probably due to local disruption of the skin barrier function or as the result of an underlying defect in general host defence (6). The occurrence of KVE in patients with DD is rare (7) and possibly caused by a disturbances in cell-mediated immunity (8). Despite abnormal findings in cellular immunity in some patients with DD, no consistent or specific abnormalities of the immune system have yet been demonstrated (6). Our patient had a decreased number of cytotoxic T-cells with normal T-cell response after antigen stimulation (in contrast with the findings of Jegasothy et al. (6)) and normal humoral response to HSV-1 infection. Recurrent KVE in our patient could be related to immune system dysfunction as an additional risk factor, along with impaired skin barrier. The excellent clinical response to IVIG speaks in favor of the role of antibody immune response in preserving the skin barrier. Occurrence of KVE in patients with mild DD (as in the case of our patient) and in some patients immediately preceding clinical skin manifestations of disease, argues very strongly against the second supposition. The severity of DD is variable and has a chronic course with frequent exacerbations and remissions. Known exacerbating triggers are: heat, sweat, sun exposure, friction, medication, and infection (9,10). The disease is chronic, and management is focused on the improvement of the skin appearance, relief of symptoms (e.g., irritation, pruritus, and malodor), and prevention or treatment of secondary infections. Topical (emollients, corticosteroids, retinoids, 5-fluorouracil, tacrolimus, pimecrolimus), physical (excision, electrodessication, dermabrasion, ablative laser, photodynamic therapy), and systemic (oral antibiotics, antiviral drugs, antimicrobial prophylaxis, vitamin A, retinoids) therapies are among the treatment options, all of which are of limited effect (2,11,12). IVIG substitution could be beneficial in some patients with Darier disease (1). In conclusion, this case highlights the association of DD with impaired cellular immunity and indicates the importance of proper diagnosis due to adequate management and avoidance of possible fatal outcomes. However, whether a subtle abnormality of T-cells in DD predisposes the patient to KVE remains unclear. Possible underlying mechanisms should be investigated further.
我们报告了一例 10 岁男孩,长期患有脂溢性皮炎 (SD),因单纯疱疹 1 型 (HSV-1) 感染和可能的原发性免疫缺陷而反复发生卡波西水痘样疹 (KVE),他被转介到过敏和免疫学部。该患者是无血缘关系父母的第二个孩子,有一个健康的哥哥。家族史无原发性免疫缺陷和皮肤疾病。该患者的皮肤问题始于婴儿期,当时他被皮肤科医生诊断并治疗 SD。从学龄前开始,他就在小儿神经科医生和缺陷学家的照顾下接受感觉处理障碍的治疗。在过去的两年里,他一直在接受氯丙嗪治疗攻击性行为。第一次 KVE 发作是在他 6 岁时被诊断出来的,当时他正在接受强效外用皮质类固醇治疗 SD 和暴露在阳光下,这是 HSV 感染的另一个已知危险因素。第三次 KVE 发作后,开始口服阿昔洛韦预防。在疾病发作期间,用局部皮质类固醇和口服抗生素治疗皮肤变化,临床反应不佳。就诊时,患者一般健康状况良好,肥胖,除额部、脸颊和颈部外侧有许多对称的黄褐色角化丘疹和斑块外,身体状况无明显异常(图 1)。指甲板有多个红色和白色的纵向条纹,以及指甲板远端游离端的 V 形缺口(图 2)。过敏测试显示总免疫球蛋白 E (IgE) 增加,对豚草过敏。免疫检查显示免疫球蛋白正常,特异性免疫良好(良好的疫苗反应和对 HSV-1 的正常体液反应),但 T 细胞数量减少(CD3+ 1020/µL(1320-3300),CD3+CD8+ 281/µL(390-1100),抗原刺激后 T 细胞反应正常)。根据病史、临床发现和组织学发现局灶性基底上棘层松解和角化不良(图 3),确诊为 Darier 病 (DD)。在开始治疗 6 个月后,开始接受低剂量口服类视黄醇治疗,获得适度的临床反应。鉴于最近的出版物(1),我们开始静脉注射免疫球蛋白 (IVIG) 替代治疗(每月 400 mg/kg),获得了极好的临床反应。治疗 4 个月后,患者的皮肤炎症减轻,结痂愈合,瘙痒减轻。继续进行阿昔洛韦预防。在随访期间,患者没有新的 KVE 发作。卡波西水痘样疹 (KVE) 或疱疹性湿疹发生在特应性皮炎 (AD)、脂溢性皮炎 (SD)、哈钦森-吉尔福德大疱性表皮松解症、过敏性接触性皮炎、银屑病和 Darier 病 (DD) 等慢性炎症性皮肤病中(2)。由于误诊或未及时治疗,死亡率很高,因此被认为是一种皮肤科急症(3)。DD 是一种罕见的常染色体显性遗传性皮肤病,具有不同的表达性,由 ATP2A2 基因突变引起,该基因编码在角质细胞中高度表达的肌浆/内质网钙 ATP 酶 (SERCA2)(4)。疾病的发作通常发生在 6 至 20 岁之间。DD 有几种临床变异型:肥厚型、疣状、水疱性-大疱性(汗疱性)、糜烂性和主要间擦性(4)。皮肤病变发生在婴儿期,且家族中无皮肤疾病史,这可能是我们最初误诊为脂溢性皮炎的原因。由于疾病的表达多样性,无法排除其他家族成员的诊断,因此计划对患者及其家庭成员进行基因检测。Darier 病患者还伴有神经精神异常,如癫痫、智力障碍和情绪障碍,这些异常在我们的患者中也存在(5),这表明了正确的诊断。DD 患者易发生严重的病毒、细菌和真菌感染,可能是由于皮肤屏障功能局部破坏或一般宿主防御功能缺陷所致(6)。DD 患者 KVE 的发生较为罕见(7),可能是由于细胞介导的免疫功能障碍引起的(8)。尽管一些 DD 患者存在细胞免疫异常,但尚未发现一致或特异性的免疫系统异常(6)。我们的患者有较少的细胞毒性 T 细胞,抗原刺激后 T 细胞反应正常(与 Jegasothy 等人的发现相反(6)),对 HSV-1 感染有正常的体液反应。我们患者的复发性 KVE 可能与免疫功能障碍有关,这是除了受损的皮肤屏障以外的另一个额外风险因素。IVIG 治疗的极好临床反应表明抗体免疫反应在维持皮肤屏障方面发挥了作用。轻度 DD(如我们患者的情况)和一些患者在疾病皮肤表现之前立即发生的 KVE 发生情况,强烈反对第二种假说。DD 的严重程度各不相同,具有慢性病程,常伴有病情加重和缓解。已知的加重诱因有:热、汗、阳光照射、摩擦、药物和感染(9,10)。这种疾病是慢性的,管理的重点是改善皮肤外观、缓解症状(如刺激、瘙痒和恶臭)以及预防或治疗继发感染。局部(保湿剂、皮质类固醇、类视黄醇、5-氟尿嘧啶、他克莫司、吡美莫司)、物理(切除、电干燥、磨皮、消融性激光、光动力疗法)和全身(口服抗生素、抗病毒药物、抗菌药物预防、维生素 A、类视黄醇)治疗是治疗选择之一,所有这些治疗都有一定的效果(2,11,12)。Darier 病患者可能受益于 IVIG 替代治疗(1)。总之,本病例强调了 DD 与细胞免疫受损的关联,并表明了由于适当的管理和避免可能致命的结果,正确诊断的重要性。然而,DD 中 T 细胞的细微异常是否使患者易发生 KVE 尚不清楚。可能的潜在机制应进一步研究。